The Washington Post
SOUTH SAN FRANCISCO -- Poniard Pharmaceuticals Inc. said Monday its
cancer drug candidate picoplatin did not help lung cancer patients live
longer, sending its shares plunging in early trading.
Poniard was running a late-stage trial of picoplatin as a secondary
treatment for non-small cell lung cancer, meaning the drug was given to
patients who had previously been treated for the disease and had a
relapse. But patients who received picoplatin did not live
significantly longer than those who received the best supportive
treatment, the company said... Read More
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
